Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sweden to merge drug and device authorities?:

This article was originally published in Clinica

Executive Summary

The Swedish authorities are considering whether medical device and pharmaceutical regulation should be dealt with by a single agency. The National Board of Health and Welfare, which includes a medical devices unit, has been holding preliminary discussions with the Medicines Products Agency to decide whether a merger would be appropriate. The Medicines Products Agency is responsible for pharmaceutical and cosmetics regulations. Several other European countries have been considering the advantages of bringing the two regulatory sectors together - France has recently set up its Agency for Healthcare Product Safety, which covers both drugs and devices, while in the UK the Medicines Control Agency and the Medical Devices Agency have decided to reject merger proposals for the time being.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT079767

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel